Arrowhead Pharmaceuticals (Germany) Performance
| HDP1 Stock | EUR 19.36 0.31 1.63% |
On a scale of 0 to 100, Arrowhead Pharmaceuticals holds a performance score of 4. The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arrowhead Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arrowhead Pharmaceuticals is expected to be smaller as well. Please check Arrowhead Pharmaceuticals' total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to make a quick decision on whether Arrowhead Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Arrowhead Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Arrowhead Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 184.4 M | |
| Total Cashflows From Investing Activities | -5.4 M |
Arrowhead |
Arrowhead Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,774 in Arrowhead Pharmaceuticals on November 3, 2024 and sell it today you would earn a total of 162.00 from holding Arrowhead Pharmaceuticals or generate 9.13% return on investment over 90 days. Arrowhead Pharmaceuticals is generating 0.2746% of daily returns assuming 5.2096% volatility of returns over the 90 days investment horizon. Simply put, 46% of all stocks have less volatile historical return distribution than Arrowhead Pharmaceuticals, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Arrowhead Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arrowhead Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arrowhead Pharmaceuticals, and traders can use it to determine the average amount a Arrowhead Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0527
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HDP1 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.21 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Arrowhead Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arrowhead Pharmaceuticals by adding it to a well-diversified portfolio.
Arrowhead Pharmaceuticals Fundamentals Growth
Arrowhead Stock prices reflect investors' perceptions of the future prospects and financial health of Arrowhead Pharmaceuticals, and Arrowhead Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arrowhead Stock performance.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X | |||
| Price To Sales | 13.82 X | |||
| Revenue | 243.23 M | |||
| EBITDA | (178.51 M) | |||
| Cash And Equivalents | 218.2 M | |||
| Cash Per Share | 2.30 X | |||
| Debt To Equity | 2.40 % | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | (136.13 M) | |||
| Earnings Per Share | (1.29) X | |||
| Total Asset | 691.94 M | |||
About Arrowhead Pharmaceuticals Performance
By analyzing Arrowhead Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Arrowhead Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arrowhead Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arrowhead Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. ARROWHEAD PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 116 people.Things to note about Arrowhead Pharmaceuticals performance evaluation
Checking the ongoing alerts about Arrowhead Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arrowhead Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arrowhead Pharmaceuticals had very high historical volatility over the last 90 days | |
| Arrowhead Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 243.23 M. Net Loss for the year was (176.06 M) with profit before overhead, payroll, taxes, and interest of 243.23 M. | |
| Arrowhead Pharmaceuticals has accumulated about 218.2 M in cash with (136.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.3. | |
| Roughly 69.0% of the company shares are owned by institutional investors |
- Analyzing Arrowhead Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arrowhead Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Arrowhead Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arrowhead Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arrowhead Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arrowhead Pharmaceuticals' stock. These opinions can provide insight into Arrowhead Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |